Castle Biosciences, Inc. (CSTL)
NASDAQ
Market Cap
$703.4M
Sector
Healthcare
Industry
Medical—Diagnostics & Research
Rank in Sector
625 of 951
Rank in Industry
37 of 52
Largest Insider Buys in Sector
CSTL Stock Price History Chart
CSTL Stock Performance
About Castle Biosciences, Inc.
Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma and myPath Melanoma, a proprietary GEP test to diagnose suspicious pigmented lesions. It offers test services through physicians and their patients. The company was founded in 2007 and is headquartered in Friendswood, Texas.
Insider Activity of Castle Biosciences, Inc.
Over the last 12 months, insiders at Castle Biosciences, Inc. have bought $0 and sold $7.98M worth of Castle Biosciences, Inc. stock.
On average, over the past 5 years, insiders at Castle Biosciences, Inc. have bought $49,058 and sold $95.72M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 4,800 shares for transaction amount of $69,004 was made by Goldberg Ellen (director) on 2023‑06‑05.
List of Insider Buy and Sell Transactions, Castle Biosciences, Inc.
| 2025-01-13 | Sale | Pres. & Chief Exec. Officer | 2,325 0.0089% | $28.05 | $65,213 | -3.48% | ||
| 2025-01-07 | Sale | Pres. & Chief Exec. Officer | 557 0.0019% | $30.14 | $16,787 | -20.86% | ||
| 2025-01-06 | Sale | Chief Commercial Officer | 2,230 0.0081% | $30.00 | $66,900 | -12.11% | ||
| 2025-01-06 | Sale | Pres. & Chief Exec. Officer | 6,236 0.0223% | $29.62 | $184,701 | -12.11% | ||
| 2025-01-06 | Sale | director | 6,442 0.0227% | $29.14 | $187,704 | -12.11% | ||
| 2024-12-17 | Sale | Pres. & Chief Exec. Officer | 9,364 0.0336% | $28.34 | $265,358 | -3.70% | ||
| 2024-12-16 | Sale | Pres. & Chief Exec. Officer | 11,059 0.0398% | $28.83 | $318,864 | -5.24% | ||
| 2024-12-13 | Sale | Pres. & Chief Exec. Officer | 14,764 0.052% | $28.64 | $422,840 | -4.81% | ||
| 2024-12-05 | Sale | Pres. & Chief Exec. Officer | 4,529 0.016% | $31.35 | $141,993 | -12.50% | ||
| 2024-12-03 | Sale | director | 6,442 0.0233% | $30.98 | $199,551 | -7.05% | ||
| 2024-11-15 | Sale | Chief Financial Officer | 6,923 0.0241% | $29.93 | $207,217 | +3.20% | ||
| 2024-11-12 | Sale | Pres. & Chief Exec. Officer | 4,529 0.0169% | $34.15 | $154,665 | -11.53% | ||
| 2024-11-05 | Sale | Chief Commercial Officer | 3,507 0.0132% | $35.56 | $124,709 | 0.00% | ||
| 2024-11-04 | Sale | Pres. & Chief Exec. Officer | 4,529 0.0156% | $32.54 | $147,362 | -12.37% | ||
| 2024-11-01 | Sale | Chief Commercial Officer | 3,100 0.0119% | $35.39 | $109,709 | -11.03% | ||
| 2024-11-01 | Sale | director | 6,442 0.0243% | $34.73 | $223,755 | -11.03% | ||
| 2024-10-14 | Sale | Pres. & Chief Exec. Officer | 4,529 0.0188% | $32.27 | $146,164 | -11.15% | ||
| 2024-10-08 | Sale | Pres. & Chief Exec. Officer | 2,264 0.0088% | $30.27 | $68,529 | +1.43% | ||
| 2024-10-07 | Sale | director | 6,442 0.0244% | $29.44 | $189,672 | +2.85% | ||
| 2024-10-04 | Sale | Pres. & Chief Exec. Officer | 2,265 0.0084% | $28.73 | $65,083 | +3.17% |
Insider Historical Profitability
24.1%
| Oelschlager Kristen M | Chief Operating Officer | 134841 0.4814% | $25.12 | 0 | 5 | |
| Juvenal Tobin W | Chief Commercial Officer | 69943 0.2497% | $25.12 | 0 | 4 | |
| Stokes Frank | Chief Financial Officer | 30823 0.1101% | $25.12 | 0 | 13 | |
| MAETZOLD DEREK J | Pres. & Chief Exec. Officer | 5104 0.0182% | $25.12 | 0 | 207 | |
| BRADBURY DANIEL | director | 1425 0.0051% | $25.12 | 0 | 123 | |
| MGC Venture Partners 2013 GP, LLC | 10 percent owner | 1464020 5.2273% | $25.12 | 1 | 3 | +21.26% |
| Sofinnova HealthQuest Partners, L.P. | 1433577 5.1186% | $25.12 | 1 | 8 | +21.26% | |
| KABAKOFF DAVID S | director | 503577 1.798% | $25.12 | 1 | 29 | +21.26% |
| Cook Joseph C. III | director | 112178 0.4005% | $25.12 | 1 | 46 | +21.26% |
| Aspinall Mara G. | director | 30848 0.1101% | $25.12 | 1 | 4 | +21.26% |
| Anderson Bonnie H | director | 21723 0.0776% | $25.12 | 0 | 5 | |
| Spiess Bernhard E. | Chief Business Officer | 13562 0.0484% | $25.12 | 0 | 8 | |
| Goldberg Ellen | director | 9065 0.0324% | $25.12 | 1 | 0 | +67.32% |
| Olson Tiffany | director | 2968 0.0106% | $25.12 | 2 | 0 | +9.58% |
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
| BlackRock | $57.49M | 9.4 | 2.6M | +13.69% | +$6.92M | <0.01 | |
| Wasatch Advisors | $56.51M | 9.24 | 2.55M | -1.54% | -$882,965.45 | 0.3 | |
| Granahan Investment Management | $36.04M | 5.89 | 1.63M | -24.89% | -$11.94M | 1.27 | |
| The Vanguard Group | $33.1M | 5.41 | 1.49M | +2.24% | +$724,194.24 | <0.01 | |
| Bellevue Group | $27.02M | 4.42 | 1.22M | -1% | -$272,289.95 | 0.41 | |
| Portolan Capital Management | $23.11M | 3.78 | 1.04M | +43.2% | +$6.97M | 1.78 | |
| Deerfield Management | $20.56M | 3.36 | 928,017 | -3.88% | -$828,653.67 | 0.05 | |
| Dimensional Fund Advisors | $16.6M | 2.71 | 749,259 | +12.86% | +$1.89M | <0.01 | |
| Soleus Capital Management, L.P. | $16.07M | 2.63 | 725,457 | +2,690.22% | +$15.49M | 0.07 | |
| Citadel Advisors LLC | $14.53M | 2.38 | 655,766 | +99.47% | +$7.24M | 0.01 | |
| Morgan Stanley | $14.41M | 2.36 | 650,711 | +36.12% | +$3.82M | <0.01 | |
| State Street | $13.42M | 2.19 | 605,799 | +4.46% | +$573,264.16 | <0.01 | |
| Geode Capital Management | $12.82M | 2.1 | 578,534 | +2.19% | +$275,120.45 | <0.01 | |
| Palisade Capital Management | $12.12M | 1.98 | 547,167 | +1.49% | +$177,908.80 | 0.36 | |
| Kornitzer Capital Management Inc Ks | $12.02M | 1.97 | 542,874 | 0% | +$0 | 0.22 | |
| Jacobs Levy Equity Management | $11.78M | 1.93 | 531,902 | -0.91% | -$108,202.75 | 0.04 | |
| Parkman Healthcare Partners Llc | $8.14M | 1.33 | 367,408 | +2.87% | +$227,081.79 | 1.01 | |
| Ameriprise Financial | $6.54M | 1.07 | 295,327 | +5.58% | +$345,540.05 | <0.01 | |
| Deutsche Bank | $5.82M | 0.95 | 262,808 | +68.65% | +$2.37M | <0.01 | |
| Millennium Management LLC | $5.51M | 0.9 | 248,553 | -65.3% | -$10.36M | <0.01 | |
| Northern Trust | $5.41M | 0.89 | 244,388 | -2.24% | -$123,929.24 | <0.01 | |
| New York State Common Retirement Fund | $5.06M | 0.83 | 228,579 | -3.6% | -$189,315.12 | 0.01 | |
| Intrinsic Edge Capital Management Llc | $4.95M | 0.81 | 223,567 | -31.48% | -$2.27M | 0.42 | |
| Next Century Growth Investors LLC | $4.86M | 0.8 | 219,473 | +2.61% | +$123,752.03 | 0.42 | |
| Acadian Asset Management | $4.67M | 0.76 | 210,824 | +130.71% | +$2.65M | 0.02 | |
| Charles Schwab | $4.54M | 0.74 | 204,937 | -1.14% | -$52,229.71 | <0.01 | |
| Renaissance Technologies | $4.53M | 0.74 | 204,700 | +82.12% | +$2.04M | 0.01 | |
| Nuveen | $4.2M | 0.69 | 189,628 | +3.92% | +$158,461.13 | <0.01 | |
| Invenomic Capital Management LP | $3.69M | 0.6 | 166,714 | -2.97% | -$112,920.70 | 0.2 | |
| Banque Pictet Cie Sa | $3.7M | 0.6 | 166,881 | -8.64% | -$349,593.44 | 0.04 | |
| Schonfeld Group | $3.66M | 0.6 | 165,441 | +2.57% | +$91,723.15 | 0.02 | |
| Bank of America | $3.35M | 0.55 | 151,165 | +9.08% | +$278,802.07 | <0.0001 | |
| Algert Global LLC | $3.22M | 0.53 | 145,407 | +12.62% | +$361,004.88 | 0.13 | |
| Advisors Capital Management | $3.13M | 0.51 | 141,115 | +15.77% | +$425,897.15 | 0.06 | |
| Goldman Sachs | $2.76M | 0.45 | 124,672 | +55.09% | +$980,868.17 | <0.01 | |
| Marshall Wace | $2.17M | 0.36 | 97,932 | +118.11% | +$1.17M | <0.01 | |
| Public Employees Retirement System Of Ohio | $2.07M | 0.34 | 93,436 | -6.8% | -$151,018.67 | 0.01 | |
| BNY Mellon | $1.86M | 0.31 | 84,105 | -9.86% | -$203,846.04 | <0.0001 | |
| Cubist Systematic Strategies | $1.81M | 0.3 | 81,744 | +16.42% | +$255,345.26 | 0.02 | |
| Connor Clark & Lunn Investment Management Ltd | $1.72M | 0.28 | 77,657 | -12.32% | -$241,723.01 | <0.01 | |
| JPMorgan Chase | $1.69M | 0.28 | 76,143 | +51.18% | +$570,960.40 | <0.0001 | |
| Orion Portfolio Solutions Llc | $1.49M | 0.24 | 67,237 | -3.58% | -$55,286.42 | 0.02 | |
| Polar Asset Management Partners Inc | $1.35M | 0.22 | 60,800 | +14.29% | +$168,340.00 | 0.03 | |
| UBS | $1.21M | 0.2 | 54,843 | +32.23% | +$296,057.03 | <0.0001 | |
| Gsa Capital Partners Llp | $1.16M | 0.19 | 52,448 | +9.05% | +$96,419.77 | 0.09 | |
| Swiss National Bank | $1.11M | 0.18 | 50,200 | 0% | +$0 | <0.01 | |
| Millrace Asset Group, Inc. | $1.1M | 0.18 | 49,773 | -36.93% | -$645,196.83 | 1.16 | |
| Barclays | $1.05M | 0.17 | 47,425 | +20.43% | +$178,118.08 | <0.0001 | |
| Envestnet Asset Management Inc | $1.02M | 0.17 | 45,927 | -8.2% | -$90,815.00 | <0.0001 | |
| Trexquant Investment LP | $996,684.00 | 0.16 | 44,997 | +291.58% | +$742,158.23 | 0.02 |
Investing Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.